Narciclasine

Narciclasine is an Amaryllidaceae alkaloid demonstrating cytostatic effects and antitumor potential by inhibiting protein biosynthesis. Its mechanism involves Rho activation in certain cancer cell lines.

Origin & History

Narciclasine is an isocarbostyril alkaloid isolated from plants of the Amaryllidaceae family, such as Narcissus and Lycoris species. It is extracted through systematic isolation from plant bulbs, with concentrations ranging from 1.5 to 200 mg/kg.

Historical & Cultural Context

There is no evidence of traditional or historical medicinal use for narciclasine. It was identified in 1967 as a plant antigrowth factor rather than for therapeutic purposes.

Health Benefits

• Exhibits cytostatic effects in animal models, inhibiting murine sarcoma cell growth [Preclinical]. • Shows potential antitumor activity in glioblastoma cell lines via Rho activation [In-vitro]. • Inhibits protein biosynthesis more potently than DNA synthesis in cellular studies [Preclinical]. • Activates RhoA GTPase, contributing to actin polymerization and cytoskeleton organization [In-vitro]. • Demonstrates antigrowth effects in wheat grain radicles at low concentrations [Early studies].

How It Works

Narciclasine primarily exerts its cytostatic effects through potent inhibition of protein biosynthesis, more significantly than DNA synthesis. In glioblastoma cell lines, it has been shown to activate Rho, contributing to its potential antitumor activity.

Scientific Research

No human clinical trials or meta-analyses have been identified; narciclasine is primarily studied in preclinical and in-vitro settings. No PMIDs for human studies are available.

Clinical Summary

Preclinical studies indicate Narciclasine inhibits murine sarcoma cell growth, demonstrating cytostatic effects in animal models. In-vitro research on glioblastoma cell lines suggests potential antitumor activity, mediated partly by Rho activation. Cellular studies further reveal its potent inhibition of protein biosynthesis compared to DNA synthesis. Currently, evidence is limited to preclinical and in-vitro investigations; human clinical trials are absent.

Nutritional Profile

Narciclasine is an isocarbostyril alkaloid extracted from Narcissus bulbs (daffodil family, Amaryllidaceae); it exhibits potent antiproliferative activity at nanomolar concentrations by inhibiting eukaryotic peptidyl transferase on the 60S ribosomal subunit and disrupting actin cytoskeleton dynamics, classifying it as a research-stage cytotoxic compound rather than a nutritional ingredient.

Preparation & Dosage

No clinically studied dosage ranges exist due to the absence of human trials. Preclinical studies report effects at concentrations of 0.05–0.5 µg/mL in cell lines. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, resveratrol, quercetin, EGCG, sulforaphane

Safety & Interactions

Given the early stage of research, comprehensive safety data for Narciclasine in humans is currently unavailable. Preclinical studies primarily focus on its therapeutic potential, not systemic toxicity or side effect profiles. Potential drug interactions, contraindications, and safety during pregnancy or lactation remain uncharacterized due to the lack of human clinical data. Caution is advised, as it exhibits potent cellular effects.